Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? (Q26830442)

Crossref

Søren M. Bentzen

series ordinal

2

1 reference

Crossref

language of work or name

1 reference

1 January 2013

1 reference

International Journal of Radiation Oncology Biology Physics

published in

1 reference

volume

85

1 reference

issue

1

1 reference

page(s)

89-94

1 reference

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Does treatment duration affect outcome after radiotherapy for prostate cancer?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Weighting bias in meta-analysis of binary outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Quantifying the position and steepness of radiation dose-response curves

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Fractionation in prostate cancer--is it time after all?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556929

Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer

28 November 2018

1 reference

12 December 2020

Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial

1 reference

12 December 2020

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

12 December 2020

A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma

1 reference

12 December 2020

How low is the alpha/beta ratio for prostate cancer?

1 reference

12 December 2020

Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy

1 reference

12 December 2020

Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer

1 reference

12 December 2020

Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial

1 reference

12 December 2020

In Response to Dr. Williams

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.IJROBP.2012.03.004

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.IJROBP.2012.03.004

1 reference

release_4pjjigxlifahjapbkn6lgklc3m

280350

Fatcat ID

0 references

280350

1 reference

1 reference

1 reference